Pfizer Financial News

(Reuters) — The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers (NYSE:BMY) Squibb and Pfizer (NYSE:PFE), that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court.

By Patrick Wingrove

By Patrick Wingrove

Brigade Enterprises has purchased land worth Rs 1,300 crore over the past year across the Southern market, to strengthen its position in the residential segment. In a recent purchase, the company bought a piece of land in Neopolis, Kokapet, Hyderabad for Rs 660 crore for a 9.7-acre plot, which translates to around Rs 68 crore per acre. The company will primarily build residential properties on this expanse of land spanning one million square feet. “We had already paid the first tranche, and we will primarily build residential on the recently purchased land. It may have some elements of other asset classes, too.

President Biden announced on Friday his intention to seek further funding from Congress to support the development of a new COVID-19 vaccine.

Pfizer and Abbott Laboratories. Investors will also watch what happens with roughly $82 billion worth of student loans held by the government whose payments will begin in October. This could sap consumer spending ahead of the holiday shopping season.

U.S. regulators have approved the first RSV vaccine for pregnant women to protect their newborns

(Reuters) -Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against emerging forms of coronavirus such as the «Eris» subvariant in small studies in animals.

immunization to help protect newborns immediately at birth through six months from RSV marks a significant milestone for the scientific community and for public health." Pfizer has said that maternal vaccination could prevent up to 16,000 hospitalizations and more than 300,000 visits to the doctor due to RSV each year if the vaccine were universally applied.

Respiratory Syncytial Virus (RSV) in their babies. The Pfizer shot, which was already approved for use in older adults, has now been greenlighted for use as a single injection from 32 through 36 weeks of pregnancy, to protect infants from birth through six months, a statement by the Food and Drug Administration said. It is the latest in a succession of medicines recently approved against the common microbe, which causes tens of thousands of hospitalizations among infants and the elderly in the United States every year, according to official estimates. Researchers have targeted an RSV vaccine since the 1960s, but the spate of shots that are emerging now were made possible thanks to a scientific breakthrough a decade ago. «RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalization,» said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. «This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.» The approval follows a clinical trial involving some 7,000 pregnant women, which showed Pfizer's vaccine, called Abrysvo, reduced severe disease caused by RSV by 82 percent in babies from 0-3 months, and 69 percent from 0-6 months. Abrysvo was previously approved by the FDA for adults aged 60 and over, as was another vaccine by drugmaker GSK, called Arexvy. While RSV most often causes mild, cold-like symptoms in infants and young children, it can also lead to more serious outcomes such as pneumonia and bronchiolitis. An estimated 58,000-80,000 children younger than five years are hospitalized due to RSV infection, according to

Joe Biden plans to urge all Americans to get a Covid-19 booster shot this autumn to counter a new wave of infections reported by the Centers for Disease Control and Prevention, said a White House official on Sunday as quoted by the news agency Reuters. Moderna on Thursday said that initial data showed its updated COVID-19 vaccine is effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other Covid-19 vaccine makers Novavax, Pfizer, and German partner BioNTech SE have created versions of their shots aimed at the XBB.1.5 subvariant.

Washington | The two pharmaceutical giants behind the lion’s share of the world’s COVID-19 vaccines have sold more than $US117 billion ($183 billion) worth of the drugs since their first big deliveries in 2021, but face a revenue cliff as the pandemic fades into history.

Pfizer, Moderna and Novavax all plan to bring boosters to the market this fall. Pfizer expects to win Food and Drug Administration approval in August, with vaccinations starting in September. Novavax said it expects to get clearance and ship doses in September, and Moderna said it is waiting for approval.

Pfizer, whose products were instrumental during the pandemic, is worth $200 billion. Until recently, though, investors in industries that help treat the consequences of obesity weren’t really sweating. But after a study was released this month showing Novo Nordisk’s Wegovy (the weight-loss version of Ozempic) helped reduce heart attacks and strokes, companies that make medical devices like glucose-monitoring systems and sleep-apnea machines plunged in value.

(Reuters) — Moderna (NASDAQ:MRNA) said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the «Eris» and «Fornax» subvariants in humans.

(Reuters) — Pfizer Inc (NYSE:PFE) said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the «Eris» subvariant in a study conducted on mice.

second Covid jab on the same arm as the first one or on the opposite arm could influence the body's immune response generated against the SARS-CoV-2 virus, new research from Germany says. Those who got jabbed on the same side, or ipsilaterally, generated more antibodies against the Covid-causing pathogen than those who got jabbed on the opposite side, or contralaterally, the study from Saarland University and other German institutes found. Further, median levels of infection-fighting CD8 T-cells generated in response to the spike-protein of the pathogen were found to be significantly lower in those contralaterally vaccinated. CD8 T-cells destroy virus-infected cells and render protection against severe disease. Consequently, after contralateral vaccination, fewer individuals (43 per cent) were found to have detectable levels of CD8 T-cells than after ipsilateral vaccination (67 per cent), the study published in the journal eBioMedicine said. Individual doses of two-dose vaccine-regimens are consecutively administered into the deltoid muscle, which is the large triangular muscle covering the shoulder joint. However, «little attention has so far been paid to the immunological effects of choosing the ipsilateral or the contralateral side for the second dose,» the authors wrote in the study.

(Reuters) -The U.S. Food and Drug Administration on Monday granted accelerated approval to Pfizer (NYSE:PFE)'s therapy for treating patients with a type of blood cancer that is difficult to treat, the company said.

By Michael Erman

adenovirus, responsible for mild cold and flu symptoms, to the occurrence of blood clotting and low platelet levels in the body. The study's findings were shared in the reputable New England Journal of Medicine.

₹93.5 crore during the quarter ending June 2023. In percentage terms, the growth is calculated a whopping 187% jump.